Next Science Limited (ASX: NXS) Share Price and News

Mr Hummel has been a partner of an Australian law firm for over fifteen years. Grant has experience with corporate and commercial transactions, with expertise in advising primary care, allied health, medical device and life science clients. He is the Chair of People and Culture Committee.

Ms Stockburger was the Worldwide Vice President of Business Development for the DePuy Synthes Group of Johnson & Johnson, where she oversaw the group's merger and acquisition activities, including deal structuring, negotiations, contract design and review, and deal terms. Aileen led Johnson & Johnson's efforts to acquire Synthes for approximately $21 billion, Johnson & Johnson's largest medical device acquisition. She also led the efforts to drive the DePuy Trauma business and acquire Micrus Endovascular. Aileen was also involved in other M&A transactions including Pfizer Consumer Healthcare (US$16.5 billion), Aveeno, BabyCenter, OraPharma, DePuy, DePuy Miket, Kodak Clinical Diagnostics and Neutrogena. She is a Member of the Risk, People & Culture Committee.

Ms Ostin was an Audit, Assurance and Risk Consulting Partner at KPMG from 2005 to 2017 and has experience in aged care and healthcare sectors, having led KPMG's New South Wales Health, Ageing and Human Services audit practice from 2006 to 2017. During her 24 years with KPMG, Kathy worked in Australia, the U.S., Asia, and the UK. She is Chair of the Risk Committee.

-

-